Therapy Areas: Autoimmune
Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801
20 July 2026 - Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/...
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
15 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has granted priority re...
Lynk Pharmaceuticals completes patient enrolment for zemprocitinib Phase III clinical trial in ankylosing spondylitis
15 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage drug development company focused on immune and inflammatory diseases, announced on Tuesday the completion of patient enrolment in the Phase...
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
13 July 2026 - Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Monday that it has received marketing authorisation in Sweden for Tofacitinib Newbury 5 mg and 10 mg ...
Antengene receives USD60m upfront payment from UCB
13 July 2026 - Chinese biotech company Antengene Corporation Limited (SEHK:6996) announced on Monday that the company has received a USD60m upfront payment from UCB (Euronext Brussels:UCB) under the w...
Teva and Polpharma Biologics enter global licensing agreement for biosimilar candidate to Ocrevus
9 July 2026 - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA), announced on Thursday that it has entered into a global licensing agre...